Drug intelligence / Profile preview

Shugan Jieyu capsule + zolpidem

Development stage
Unknown
Lead developer
Chengdu Kanghong Biotechnology
Modality
Small Molecules
Administration
Oral
01

Overview

Shugan Jieyu capsule + zolpidem is a combination therapy consisting of Shugan Jieyu capsule, a traditional Chinese medicine (TCM) formulation, and zolpidem, a non-benzodiazepine hypnotic pharmaceutical. **Shugan Jieyu capsule** contains extracts from Hypericum perforatum (St. John's Wort) and Acanthopanax senticosus (Siberian ginseng). It is primarily used in China for the treatment of depression, anxiety, insomnia, and post-stroke depression. Its mechanisms include increasing dopamine and serotonin (5-HT) secretion to improve mood and nerve excitability; it also has anti-fatigue, anti-stress effects via central nervous system modulation[1][3]. The main active constituent hypericin provides antidepressant effects. **Zolpidem** is an FDA-approved small molecule drug used for short-term management of insomnia. It acts as a central nervous system depressant by enhancing GABAergic neurotransmission through selective agonism at the benzodiazepine site of the GABA-A receptor complex[2][4]. This results in sedative-hypnotic effects that help initiate and maintain sleep. The combination may be considered for patients with comorbid insomnia and mood disorders such as anxiety or depression[1], though clinical evidence on their combined use is limited.

02

Targets

SERT (Sodium-dependent serotonin transporter)GABAA (Gamma-aminobutyric acid receptor)DAT (Dopamine plasma membrane transport protein)

Beyond the preview

Go deeper on Shugan Jieyu capsule + zolpidem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shugan Jieyu capsule + zolpidem.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call